GILEAD SCIENCES SL
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)
- Conditions
- Interventions
- First Posted Date
- 2019-06-14
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 109
- Registration Number
- NCT03987074
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Institute for Liver Health - Arizona Liver Health, Chandler, Arizona, United States
🇺🇸Quality Medical Research, PLLC, Nashville, Tennessee, United States
Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 165
- Registration Number
- NCT03964727
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸Arizona Oncology Associates PC-HAL, Goodyear, Arizona, United States
🇦🇺Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia
Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 62
- Registration Number
- NCT03960645
- Locations
- 🇩🇴
Instituto Dominicano de Estudios Virologics (IDEV), Santo Domingo, Dominican Republic
🇹🇭Thai Red Cross AIDS Research Centre, Pathumwan, Thailand
🇹🇭Faculty of Medicine-Khon Kaen University, Khon Kaen, Thailand
Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 22
- Registration Number
- NCT03954704
- Locations
- 🇺🇸
Scottsdale Healthcare Hospitals d/b/a HonorHealth, Scottsdale, Arizona, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
🇺🇸Mary Crowley Cancer Research, Dallas, Texas, United States
Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers
- Conditions
- Interventions
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 8
- Registration Number
- NCT03912831
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 543
- Registration Number
- NCT03901339
- Locations
- 🇺🇸
The University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Maryland Oncology Hematology, P.A., Rockville, Maryland, United States
Study of Cilofexor in Adults With Primary Sclerosing Cholangitis
- First Posted Date
- 2019-03-26
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 419
- Registration Number
- NCT03890120
- Locations
- 🇺🇸
Texas Clinical Research Institute, Arlington, Texas, United States
🇺🇸Ruane Clinical Research Group Inc., Los Angeles, California, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)
- Conditions
- Interventions
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 175
- Registration Number
- NCT03852433
- Locations
- 🇷🇺
LLC Medical Company "Hepatolog", Samara, Russian Federation
🇷🇺Federal Budget Institute of Science "Central Research Institute for Epidemiology" of Federal Service on Consumers Rights Protection and Human Well-Being Surveillance, Moscow, Russian Federation
🇷🇺State Budgetary Educational Institution of Higher Professional Education "South Ural State Medical University" of the Ministry of Healthcare of the Russian Federation, Chelyabinsk, Russian Federation
Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 150
- Registration Number
- NCT03852719
- Locations
- 🇩🇪
Universitätsklinikum Frankfurt Medizinische Klinik 1, Frankfurt am Main, Germany
🇮🇹Università di Modena e Reggio Emilia- Ospedale Civile S., Modena, Italy
🇺🇸Cornell University Well Madical College, New York, New York, United States
Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection
- First Posted Date
- 2019-01-29
- Last Posted Date
- 2020-10-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 21
- Registration Number
- NCT03820258
- Locations
- 🇮🇹
SOS-intraSOC Epatologia, Firenze, Italy
🇮🇹US Infettivologia Pediatrica-Polo Universitario, Milano, Italy
🇮🇹Servizio di Epatologia e Nutrizione Pediatrica, Milan, Italy